8-K 1 a2059923z8-k.txt 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 September 25, 2001 Date of Report BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-1136 22-079-0350 (Commission File Number) (IRS Employer Identification Number) 345 Park Avenue, New York, NY 10154 (Address of principal executive offices) (Zip Code) (212) 546-4000 Item 5. OTHER EVENTS Incorporated by reference in its entirety is a press release issued by the registrant on September 25, 2001, attached as exhibit 99.1, concerning the registrant's announcement that it expects to re-file its New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for VANLEV(R). Item 7. FINANCIAL STATEMENTS AND EXHIBITS (a) Financial Statements Inapplicable. (b) Pro Forma Financial Information Inapplicable. (c) Exhibit. 99.1 Press Release dated September 25, 2001. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRISTOL-MYERS SQUIBB COMPANY By: /s/ Sandra Leung ------------------------------- Name: Sandra Leung Title: Corporate Secretary EXHIBIT INDEX
Exhibit No. Description of the Exhibit ----------- -------------------------- 99.1 Press Release dated September 25, 2001